title: Is there a role for indinavir twice-daily in clinical practice?
authors.affiliation: Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain.
authors.forename: P
authors.initials: P
authors.lastname: Barreiro
authors.forename: V
authors.initials: V
authors.lastname: Soriano
authors.forename: N
authors.initials: N
authors.lastname: Cabello
authors.forename: J
authors.initials: J
authors.lastname: González-Lahoz
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D019469:Indinavir / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D013030:Spain; D018119:Stavudine / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D019469:Indinavir; D018119:Stavudine